Amycretin
Amycretin is a single molecule serving as a GLP-1 receptor agonist and an amylin receptor agonist. It is made by the Danish pharmaceutical company Novo Nordisk as a weight loss drug to be taken by mouth.[1] A form that can be injected via human skin is also under study.[1]
Mechanism of action
The drug has a dual mechanism of action affecting appetite regulation and metabolism,[2] which makes it different from other drugs being made for weight loss.[2]
Research
The company announced the results from the Phase I trial of amycretin's pill form.[3] The company further announced the results of its 1B/2A trial in January 2025.[4] The trial investigated the drug's safety, tolerability, and pharmacokinetics by injecting it into 125 patients via their skin.[4] The treatment lasted up to 36 weeks.[4]
References
- ↑ 1.0 1.1
- Jamaluddin, Aqfan. RISING STARS: Targeting G protein-coupled receptors to regulate energy homeostasis. Journal of Molecular Endocrinology 70 (4) (2023-03-21)Bioscientifica. doi:10.1530/jme-23-0014.
- Melson, Eka. What is the pipeline for future medications for obesity? (in en). International Journal of Obesity (February 1, 2024). p. 1–19. doi:10.1038/s41366-024-01473-y.
- Goldenberg, Ronald M.. Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists. Obesity Reviews 25 (3) (2024). doi:10.1111/obr.13663.
- Linnane, Ciara. "Viking Therapeutics faces higher bar for oral weight-loss drug" (in EN-US). MarketWatch. https://www.marketwatch.com/story/viking-therapeutics-faces-higher-bar-for-oral-weight-loss-drug-after-strong-readout-from-rival-72c531c4. Retrieved March 11, 2024.
- Goldenberg, Ronald M.. Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists. Obesity Reviews 25 (3) (2024). doi:10.1111/obr.13663.
- ↑ 2.0 2.1 Safety, tolerability and weight reduction findings of oral amycretin: a novel amylin and glucagon-like peptide-1 receptor co-agonist, in a first-in-human study.. Diabetologia 67 (September 2024)Springer. p. S42-S43.
- ↑ "Novo valuation surpasses Tesla on experimental obesity drug data". Reuters (March 7, 2024). Retrieved 2024-03-13.
- ↑ 4.0 4.1 4.2 Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity (in en). Novo Nordisk (January 24, 2025). Retrieved 2025-01-29.
